Therapeutic immunisation with recombinant gp160 in HIV-1 infection: A randomised double-blind placebo-controlled trial

Lancet

Volumn 353, Issue 9166, 1999, Pages 1735-1742

  Sandström, Eric ^a   Wahren, Britta ^b  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT PROTEIN;

ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FINLAND; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOREACTIVITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NORWAY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SWEDEN;

EID: 0033594730     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)06493-9     Document Type: Article

References (30)

1. Philllips AN. Reduction of HIV concentration during acute infection: independence from a specific immune response. Science 1996; 271: 497-99.
2. Rowland-Jones S, Tan R, McMichael A. Role of cellular immunity in protection against HIV infection. Adv Immunol 1997; 65: 277-346.
3. Heeney JL, Beverly P, McMichael A, et al. Understanding the immune correlates of protection from HIV infection and disease progression to AIDS: more answers but yet more questions. Immunol Today (in press).
4. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278: 1447-51.
5. Björndal Å, Deng H, Jansson M, et al. Coreceptor useage of primary immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997; 71: 7478-87.
6. Wahren B, Morfeldt-Månsson L, Biberfeld G, et al. Impaired specific cellular response to HTLV-III before other immune defects in patients with HTLV-III infection. N Engl J Med 1986; 315: 393-94.
7. Shearer GM, Bernstein DC, Tung KS, et al. A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS). J Immunol 1986; 137: 2514-21.
8. Harrer T, Harrer E, Kalams SA, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection: breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 1996; 156:2616-23.
9. Loomis-Price LD, Cox JH, Mascola JR, et al. Correlation between humoral responses to HIV-1 envelope and disease progression in early-stage infection. J Infect Dis 1998; 178: 1306-16.
10. Pantaleo G, De Maria A, Koenig S, et al. CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity. Proc Natl Acad Sci USA 1990; 87: 4818-22.
11. Leandersson A-C, Bratt G, Hinkula J, et al. Induction of specific T-cell responses in HIV infection. AIDS 1998; 12: 157-66.
12. Bratt G, Karlsson A, Leandersson A-C, Albert J, Wahren B, Sandström E. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. AIDS 1998; 12: 2193-202.
13. Redfield RR, Birx DL, Ketter N, et al. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991; 324: 1733-35.
14. Eron JJ Jr, Ashby MA, Giordano MF, et al. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996; 348: 1547-51.
15. Trauger RJ, Daigle AE, Giermakowska W, Moss RB, Jensen F, Carlo DJ. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 10 (suppl 2): S74-82.
16. Biselli R, Loomis LD, Del Bono V, Burke DS, Redfield RR, Birx DL. Immunization of HIV-infected patients with rgp160: modulation of anti-rgp120 antibody spectrotype. J Acquir Immune Defic Syndr 1994; 7: 1016-24.
17. Wahren B, Bratt G, Persson C, et al. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr 1994; 7: 220-29.
18. Kundu SK, Katzenstein D, Moses LE, Merigan TC. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine. Proc Natl Acad Sci USA 1992; 89: 11204-08.
19. Fouts TR, Binley JM, Trkola A, Robinson JE, Moore JP. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol 1997; 71: 2779-85.
20. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-81.
21. Birx DL, Davis C, Ruiz N, et al. Results of a phase II double-blind multicenter, placebo controlled HIV therapeutic vaccine trial. XI International Conference on AIDS. Vancouver, July, 1996 (abstr TuA175).
22. Tsoukas CM, Raboud J, Bernard NF, et al. Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immune deficiency. AIDS Res Hum Retroviruses 1998; 14: 483-90.
23. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life span and viral generation time. Science 1996; 271: 1582-86.
24. Loomis LD, Deal CD, Kersey KS, Burke DS, Redfield RR, Birx DL. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160. J Acquire Immune Defic Syndr Hum Retroviral 1995; 10: 13-26.
25. Ponteselli O, Guerra EC, Ammassari A, et al. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. AIDS 1998;12:473-80.
26. Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA. Within-subject variation in CD4 lymphocyte count in asyptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis 1994; 169: 28-36.
27. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997; 3: 533-40.
28. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-300.
29. Kaufmann D, Pantaleo G, Sudre P, Telenti A for the Swiss HIV Cohort Study. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998; 351: 723-24.
30. Corey L, McElrath MJ, Weinhold K, et al. Cytotoxic T cell neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. J Infect Dis 1998; 177: 301-09.